Breaking News

Human Insulin Market 2019-2026 Study & Future Prospects Including Key Players- Sanofi, Novo Nordisk A/S, Eli Lilly and Company, Biocon Ltd., Julphar

img

Market Size – USD 24.87 Billion in 2018, Market Growth – CAGR of 8.1%, Market Trends – Product launches and research for advanced pruritus therapeutics

According to the current analysis of Reports and Data, the global Human Insulin market was valued at USD 24.88 Billion in 2018 and is expected to reach USD 46.59 Billion by year 2026, at a CAGR of 8.1%. The study covers insulin, an industrially manufactured replica of a peptide hormone produced by the pancreas for people whose bodies can’t produce it on their own. Insulin is considered to be the primary anabolic hormone which is responsible for the conversion of small molecules in the blood into large molecules inside the cells. Low insulin levels in the blood promotes catabolism, which is the conversion of large molecules into smaller ones, especially of reserve body fat which may lead to numerous complications like loss of vision, unsteadiness of limbs, and obesity. A patient is prescribed different types of insulin based on many factors including their response to insulin and the patient’s diet, alcohol intake and exercise to combat this lack of insulin.

Here, you can avail sample PDF pages and 30 mins free consultation: https://www.reportsanddata.com/sample-enquiry-form/2026

Rise in prevalence of diabetes and obesity, increase in unhealthy lifestyle habits, mergers and acquisitions by major companies, product launches, technological advancements, the development of more effective and efficient  Insulin, and a favorable research funding scenario, are some of the key factors propelling market growth in the industry. However, an highly monopolized market, associated side effects like risk of skin infections at the catheter site, diabetic ketoacidosis, extremely high costs of drug and device and the hassle of checking blood glucose times per day may cause the consumer to opt out of insulin treatment which is expected to hamper the market are the major hindrance for market growth during 2019-2026.

Further key findings from the report suggest

  • Human Insulin market is growing at a CAGR of 9.3% in Asia Pacific followed by North America and Europe, with 8.0% and 7.7% CAGR, respectively. Rise in prevalence of obesity and diabetes across the globe is the key factor to accelerate the market growth during forecast period across all regions.
  • As of 2018, Insulin drugs dominates the market holding 84% of the global market since insulin is a daily requirement for diabetic patients and is consumed everyday
  • On the basis of application, Type II Diabetes is expected to be the fastest growing market segment during forecast period 2019-2026 with a CAGR of 8.3%
  • Type II application segment holds a market share of 92% since most diabetic patients are type II diabetics, followed by type I diabetes, holding an 8% market share as it is a rare type of diabetes
  • Asia Pacific is expected to account for the 17.9% of the global Human Insulin market due to the large prevalence of diabetes and obesity in countries like India and China
  • Extremely high costs, highly monopolized market, and assosciated side effects are the key challenges faced by the Insulin market players
  • Key participants include Sanofi (France), Novo Nordisk A/S (Denmark), Eli Lilly and Company (U.S.), Biocon Ltd. (India), Julphar (U.A.E.), Ypsomed AG (Switzerland), Becton, Dickinson and Company (U.S.), Wockhardt Ltd. (India), B. Braun Meselgen AG (Switzerland), and Biodel Inc. (U.S.)

Connect with an expert for customization of Report @ https://www.reportsanddata.com/sample-enquiry-form/2026

For the purpose of this report, Reports and Data has segmented the Human Insulin market on the basis of product type, drug type, device type, application, and region:

Product Type Outlook (Revenue, USD Million; 2016-2026)

  • Drugs
  • Delivery Devices

Drug Type Outlook (Revenue, USD Million; 2016-2026)

  • Insulin Analogs and Biosimilars
    • Long-Acting Biosimilars
    • Rapid-Acting Biosimilars
    • Premixed Biosimilars
  • Human Insulin Biologics
    • Short-Acting Biologics
    • Intermediate-Acting Biologics
    • Premixed Biologics

Device Type Outlook (Revenue, USD Million; 2016-2026)

  • Pens
    • Disposable Pens
    • Reusable Pens
  • Pen Needles
    • Standard Pen Needles
    • Safety Pen Needles
  • Syringes

Application Outlook (Revenue, USD Million; 2016-2026)

  • Type I Diabetes
  • Type II Diabetes

Regional Outlook (Revenue, USD Million; 2016-2026)

  • North America (U.S., Canada)
  • Europe (Germany, France, UK, Spain, Italy, Rest of the Europe)
  • Asia Pacific (China, India, Japan, Rest of Asia-Pacific)
  • Middle East & Africa
  • Latin America (Brazil)

For Further Details about this Market Visit: https://www.reportsanddata.com/report-detail/human-insulin-market

About Us:
Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target and analyze consumer behavior shifts across demographics, across industries and help client’s make a smarter business decision. We offer market intelligence studies ensuring relevant and fact-based research across a multiple industries including Healthcare, Technology, Chemicals, Types, and Energy. We consistently update our research offerings to ensure our clients are aware about the latest trends existent in the market.

Email

Go to website